Board of Directors
Dick Allen
Dick Allen is Chairman of the Board for Tandem Diabetes Care. He has 40 years of experience in the health care industry, both as an operating executive and as a seed capital investor/board member.
Mr. Allen started his career at Baxter Healthcare, holding domestic and international management positions in both finance and operations during his tenure. After leaving Baxter, Mr. Allen co-founded Caremark and oversaw the finance, operations and administration functions for this venture-backed pioneer of home infusion therapy. Since Caremark's sale to Baxter in 1987, Mr. Allen has been President of DIMA Ventures, a privately-held firm that provides seed capital and board support for health care start-ups. In this capacity, he has been a founder, board member, or early-stage private investor in over 25 companies. Additionally, he co-founded Pyxis Corporation, a manufacturer and marketer of hospital-based automated prescription drug storage and dispensing devices, and served on the executive committee of the board of directors until the sale of the company to Cardinal Health in 1996.
Presently, Mr. Allen teaches at Stanford University Graduate School of Business. He is the Chairman of the Orange County Community Foundation and Chairman of the Research Development Committee of the Juvenile Diabetes Research Foundation (JDRF). He is a past Chairman of Hoag Memorial Hospital Presbyterian and currently serves on the boards of JDRF International and several privately-held health care companies. Mr. Allen holds a MBA from Stanford University Graduate School of Business and a BS (cum laude) from Yale University.
Back to Top
Kim Blickenstaff
Kim Blickenstaff is President, Chief Executive Officer and a Board Member of Tandem Diabetes Care. He joined Tandem in August 2007, bringing more than 30 years of health care experience in finance, marketing management, sales and strategic planning.
Prior to joining Tandem, Mr. Blickenstaff was Chairman, Chief Executive Officer and co-founder of Biosite Incorporated, a medical diagnostic company that was acquired by Inverness Medical Innovations for $1.8 billion in June 2007. Prior to founding Biosite, he held various finance, operations, research management, sales management, strategic planning and marketing positions with Hybritech Incorporated and Baxter Healthcare.
Mr. Blickenstaff has been active in the medical device and diagnostics industry over the last 14 years, serving on the board of directors for innovative, young healthcare companies such as SenoRx and MediVation Incorporated. He holds a Masters of Business Administration from Loyola University Chicago’s Graduate School of Business.
Back to Top
Howard (Ted) Greene, Jr.
Howard (Ted) Greene, Jr. is an accomplished entrepreneur and investor in the biotechnology industry. During a business career spanning over three decades, Mr. Greene has gained experience in various aspects of early stage medical technology companies. Both as an inventor and entrepreneur, and as a venture capitalist, he has been involved in starting, funding, and/or managing ten technology-driven enterprises, all of which have gone public.
Prior to his retirement in 1998, Mr. Greene was Chairman of Amylin Pharmaceuticals, Inc., a company he co-founded in 1987 that has launched two first-in-class diabetes drugs. Mr. Greene holds several patents directed to using the hormone amylin in diabetes therapy. Before starting Amylin, Mr. Greene co-founded Biovest Partners, a venture capital firm that in two years provided seed capital and management leadership for six medical technology start-up companies, including Amylin, and that returned about ten-fold its limited partners’ investment in less than five years. All six companies were taken public, and four of them– Pyxis Corporation, Neurex Corporation, Epimmune Inc, and Biosite Incorporated – have been acquired. The other two – Amylin and Vical – remain publicly traded companies.
Prior to Biovest, Mr. Greene was Chief Executive Officer of Hybritech Incorporated, essentially from inception until its acquisition by Eli Lilly and Company in 1986. Before Hybritech, Mr. Greene was an executive with Baxter Healthcare Corporation for five years, and prior to that he was a consultant with McKinsey & Company for seven years. He is presently a director of several early stage startups in the biotech and internet fields. Mr. Greene holds a Masters of Business Administration from Harvard University and a BA in physics from Amherst College.
Back to Top
John Livingston
John Livingston’s career in medical device product development spans more than 30 years. Following positions at Cordis Corporation, IMED, and Pacesetter Systems, he spent 16 years with MiniMed, a startup manufacturer of ambulatory infusion pumps and glucose sensors to meet the needs of people with diabetes.
Mr. Livingston was the senior Research, Development and Engineering executive at MiniMed. MiniMed went public in 1995 and was acquired by Medtronic in 2001. His career at MiniMed also included activities and responsibility for Manufacturing, Regulatory Affairs, Legal Affairs, Grants Management, and University Relations.
Mr. Livingston is a USAF veteran and earned his BS (cum laude) in Engineering and Applied Science from Yale University, an MSEE from Stanford University, and a JM from Stanford School of Law. He is a registered Professional Engineer and a Patent Agent and has twenty patents. He has been a consultant and advisor to a number of startup medical device companies, and a resource staff member at Select University Technologies, Inc. In addition, Mr Livingston is a member of the Clinic Advisory Committee at Harvey Mudd College, and a core team member of Tapestry Homes, a faith-based non-profit social enterprise with the purpose of providing durable homes to the landless poor in urban areas worldwide.
Back to Top
Paul DiPerna
Paul DiPerna is Founder, Chief Technical Officer and Board Member of Tandem Diabetes Care. He has more than 25 years of progressive experience in complex electro-mechanical mechanisms, technical management and business management in the automated test and 18 of those years in the medical device industry.
Prior to forming Tandem, Mr. DiPerna was Senior VP of Technology and Operations at Hepahope, a startup company developing liver dialysis systems for end stage liver failure patients. Prior to that position, Mr. DiPerna worked at Baxter Healthcare for 14 years where he held progressive management positions; first as a Technologist for cell separation systems, then as Program Manager of the largest and most complex system Baxter had undertaken, next as Director of Business Development in the corporate technology group, and finally as General Manager of Digital Dental Sciences, a start-up within the Baxter organization.
Mr. DiPerna received a Masters in Engineering Management from Northeastern University and a BS in Mechanical Engineering from the University of Massachusetts Lowell. He is a member of the American Diabetes Association and the American Society of Clinical Oncology.
Back to Top
Jesse Treu
Jesse Treu has been a Partner of Domain Associates, LLC since its inception in 1985. In addition, he has been a Director for more than 30 early-stage health care companies, of which 18 thus far have become successful public companies.
Mr. Treu has served as a Founder, President and Chairman of numerous venture stage companies. Prior to the formation of Domain, Mr. Treu had 12 years of experience in the health care industry. He was Vice President of the predecessor organization to The Wilkerson Group and its venture capital arm, CW Ventures. He has served as President and CEO of Microsonics. Prior to that time, Mr. Treu led new product development and marketing planning for Technicon Corporation (now Siemens Medical Solutions Diagnostics). He began his career with General Electric, initially as a research scientist and subsequently serving on the corporate staff with responsibility for technology assessment and strategic planning.
Mr. Treu’s present board memberships include Aesthetic Sciences, Altea Therapeutics, BiPar Sciences, CoLucid, Regado Biosciences, and Somaxon Pharmaceuticals. Mr. Treu received a Ph.D. and M.A. from Princeton University and a B.S. from Rensselaer Polytechnic Institute.
Back to Top
Ned Brown
Ned Brown is Managing Director at Texas Pacific Group (TPG).
Prior to joining TPG Biotech in 2007, Mr. Brown co-founded Healthcare Investment Partners (HIP), a private equity fund focused exclusively on health care, and served as a Managing Director of HIP since its inception in June 2004. Before forming HIP, Mr. Brown had over seventeen years of experience in health care investment banking, most recently as a Managing Director at Credit Suisse First Boston, where he led the firm's West Coast health care effort and was one of the senior partners responsible for the firm's global life sciences practice, from August 2000 to June 2004.
Mr. Brown serves on the board of directors of Angiotech Pharmaceuticals, Inc., Oculus Innovative Sciences, and Replidyne, Inc. Mr. Brown received his Master of Business Administration from UCLA and a BA in English from Middlebury College, and attended graduate school at Oxford University in English Literature.
Back to Top
Doug Roeder
Doug Roeder joined Delphi Ventures as an Associate in 1998 and became a Partner in 2000. His primary investment focus at Delphi is on medical devices and diagnostics.
Prior to joining Delphi, Mr. Roeder was an Associate with Alex. Brown & Sons Healthcare Investment Banking Group in San Francisco. While at Alex. Brown & Sons, Mr. Roeder assisted in the execution of over a dozen financing and merger transactions involving both Fortune 500 and venture-backed medical technology companies, including a number of Delphi portfolio companies. Previously, Mr. Roeder was with Putnam Associates, a consulting firm focused on the biopharmaceutical industry, where his primary role was to develop and implement a strategy for the launch of a leading biotech drug.
Mr. Roeder received an AB from Dartmouth College and has been involved with Anulex Technologies, Inc., Evalve, Inc., Ivantis, Inc., Labcyte, Inc., Soteira, Inc., TranS1, Inc. (TSON), TriVascular, Inc. a.b. Boston Scientfic Corp. (BSX), TriVascular 2, Inc., and Vibrynt, Inc.
Back to Top
Ed Cahill
Edward L. Cahill is a Partner of HLM Venture Partners.
Previously, Mr. Cahill was a founding Partner of Cahill, Warnock & Company (now Camden Partners), a Baltimore venture capital firm, and a Managing Director of Alex. Brown & Sons, where he headed the firm's Health Care group from 1986 to 1995.
During his leadership at Alex. Brown & Sons, the firm underwrote public offerings or provided merger advisory services for over 200 health care companies, including the first outpatient surgery, rehabilitation, and managed care companies to go public, and several leading biopharmaceutical companies.
Mr. Cahill is a director of Masimo Corporation, Phreesia and Prism Education Group. He previously served as a director of Animas Corporation, Centene Corporation (NYSE), Spinal Concepts and Automated Healthcare and Gene Medicine (NASDAQ). He is a Trustee of Johns Hopkins Medicine, The Johns Hopkins Hospital and Health System and Mercy Health Services.
Mr. Cahill received an AB from Williams College and a Master of Public and Private Management degree from Yale University.